NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY), DENTSPLY International Inc. (NASDAQ: XRAY), Pharmacyclics Inc. (NASDAQ: PCYC), and St. Jude Medical Inc. (NYSE: STJ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Merck & Co., Inc. Research Report
On December 20, 2013, Merck & Co., Inc. (Merck) announced the launch of a new business centeredon providing comprehensive, evidence-based weight management interventions in the US. According to the Company, this business is based on providing weight management interventions for employers, hospitals, medical groups, health plans, and patients, bringing together a structured diet, behavior coaching and monitoring, and physical activity to achieve clinically meaningful weight loss, thereby reducing the risk of chronic illnesses, including diabetes and cardiovascular disease. The Company informed that HMR Weight Management Service Corporation, a new company that brings together the capabilities of Merck and assets from Health Management Resources Corporation (HMR), was created to bring these interventions to the market more effectively. Merck added that HMR will operate as a subsidiary of the Company. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Bristol-Myers Squibb Co. Research Report
On December 19, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) announced that the Company's Board of Directors declared a quarterly dividend of $0.36 per share on the $0.10 par value Common Stock of the corporation for Q1 FY 2014. Bristol-Myers Squibb reported that the said dividend will be payable on February 3, 2014 to stockholders of record at the close of business on January 3, 2014. The Company's Board of Directors further declared a quarterly dividend of $0.50 per share on the $2.00 Convertible Preferred stock of the corporation, payable March 3, 2014 to stockholders of record at the close of business on February 7, 2014. The Full Research Report on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
DENTSPLY International Inc. Research Report
On December 20, 2013, DENTSPLY International Inc.'s (DENTSPLY) stock rose 0.21%, ending the day at $48.43. Over the previous three trading sessions, shares of DENTSPLY gained 2.04%, compared to the Nasdaq Composite which gained 2.01% during the same period. The Full Research Report on DENTSPLY International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Pharmacyclics Inc. Research Report
On December 20, 2013, Pharmacyclics Inc.'s (Pharmacyclics) stock rose 2.41%, ending the day at $103.85. Over the previous three trading sessions, shares of Pharmacyclics gained 4.16%, compared to the Nasdaq Composite which gained 2.01% during the same period. The Full Research Report on Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
St. Jude Medical Inc. Research Report
On December 18, 2013, St. Jude Medical Inc. (St. Jude Medical) announced that the Company is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference on January 13, 2014, in San Francisco. The Company's Chairman, President and CEO, Daniel J. Starks, will address the conference at 11:00 a.m. PST. St. Jude Medical also informed that interested parties may access a live webcast of the presentation at the Company website. The Full Research Report on St. Jude Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner